Interim Report 1 July – 30 September 2020
“I am pleased with the performance during the third quarter of 2020. First and foremost, we experienced a continued increase in the clinical usage of the Episealer® technology, best evidenced by a record 88 Episealer® orders approved. This figure represents an increase of 57% compared to the same period in 2019, and a 76% increase compared to Q2 2020. We have increased the number of users during the year, and surgeries have taken place 12 countries during 2020. We are creating a strong foundation for the future, and I believe this growth is impressive during the experimental and clinical